Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis

Morie A. Gertz(Mayo Clinic), Ray Comenzo(Memorial Sloan Kettering Cancer Center), Rodney H. Falk(Boston University), Jean Paul Fermand(Université Paris Cité), Bouke P. C. Hazenberg(University of Groningen), Philip N. Hawkins(UCL Australia), Giampaolo Merlini(University of Pavia), Philippe Moreau(Centre Hospitalier Universitaire de Nantes), Pierre Ronco(Inserm), Vaishali Sanchorawala(Boston University), Orhan Sezer(Humboldt-Universität zu Berlin), Alan Solomon(University of Tennessee at Knoxville), G Grateau(Hôtel-Dieu de Paris)
American Journal of Hematology
January 1, 2005
Cited by 1,413

Abstract

We undertook this study to develop uniformly accepted criteria for the definition of organ involvement and response for patients on treatment protocols for immunoglobulin light-chain amyloidosis (AL). A consensus panel was convened comprising 13 specialists actively involved in the treatment of patients with amyloidosis. Institutional criteria were submitted from each, and a consensus was developed defining each organ involved and the criteria for response. Specific criteria have been developed with agreed on definitions of organ and hematologic response as a result of discussions at the 10th International Symposium on Amyloid and Amyloidosis held in Tours, France, April 2004. These criteria now form the working definition of involvement and response for the purposes of future data collection and reporting. We report criteria that centers can now use to define organ involvement and uniform response criteria for reporting outcomes in patients with light-chain AL.


Related Papers

No related papers found

Powered by citation graph analysis